

Index to Volume 26

Index of Issues: January, 1-66; February, 67-120; March, 121-190; April, 191-242; April Supplement, S1-S52; May, 243-308; July, 309-368; August, 369-420; September, 421-490; October, 491-548; November, 549-608

INDEX OF AUTHORS

A

Abdool Karim SS, 152
Adler N, 208
Alary M, 317, 410
Ali-Napo L, 191
American Social Health Association
 Panel, S2
Anglin MD, 82
Aral SO, 262
Aramburn J, 103
Artz L, 127, 450
Ashley R, 221
Augenbraun M, 143
Austin H, 127, 329, 450
Averinou H, 43

B

Bacchetti P, 143

Bachmann L, 87, 272, 496

Baer JT, 335

Ballard RC, 556

Barkan S, 143

Barker K, 508

Baseman J, 444

Bastani R, 463

Beauchamp D, 177

Beckham C, 213

Beebe JL, 579

Benedetti J, 221

Bensen C, 364

Bergeron MG, 177

Berglund T, 390

Bernier F, 410

Bernstein DI, 438

Beutner K, 364

Biro FM, 472

Blackwelder T, 137

Blythe MJ, 26

Bock JE, 325

Boisvert J-F, 392

Bolan G, 335

Bollinger R, 55

Bonard D, 191

Bonney MS, 49

Borthagaray G, 157

Boyd MA, 543

Brewer DD, 166

Brizendine EJ, 26

Buchbinder S, 564

Bull SS, 584

Burns D, 143

C

Caceres CF, 103

Carey RF, 216

Casabona J, 500

Castellano T, 103

Castello Daly C, 381

Cates W Jr, 459, S2

C

Celum CL, 564, 572

Chakraborty H, 381

Chan RKW, 593

Chan-Tack K, 55

Chernesky M, 504, S8

C

Chesney MA, 572
Chou C-P, 82
Chua WL, 593
Clemens CM, 160
Cohen MS, 381
Cohen SS, 472
Cole PA, 87
Coles FB, 296
Coletti AS, 564, 572
Combe P, 191
Conant M, 364
Conrad N, 527
Contento KM, 335
Coplan PA, 184
Corey L, 1, 221
Cormier H, 177
Coronado N, 543
Coughlin S, 108
Creede P, 579
Crosby RA, 399
Cullen AP, 303
Cyr WH, 216

D

Dallabetta G, S12
Dalu ZA, 531
Davis G, 364
Delapenha R, 143
DeLisle S, S28, 339
Désormeaux A, 177
DeVellis RF, 472
Dhéda H, 191
Diamond C, 221
Divekar A, 55
Divekar AA, 358
Dobbins JG, 67
Dorst D, 281
Dosso M, 191
Dufour A, 317
Dunlop MBV, 208

E

Ellen JM, 208
Ellish N, 75
Eubanks C, 537
Everett W, S49
Ewell J, 201

F

Farley TA, 108, 201
Faxelid E, 491
Faye-Ketté H, 191
Fenner DE, 137
Fife KH, 226
Finch M, S23
Fleenor M, 127, 329, 450
Flemtakis A, 43
Fleming TR, 564
Foglia G, 421
Ford JA, 87
Ford K, 17
Forman P, 556
Fortenberry JD, 26, 584
Frangouli E, 43
Fredlund H, 390
Fresia A, 75

G

Gadkari D, 55
Gagfie N, 177
Gangakhedkar RR, 55
Garcia P, 143
Garrett SB, 166
Gaydos C, 55, 519
Gaydos JC, 519
Gershman KA, 579
Gift TL, 232
Glass G, 75
Gogate AS, 358
Goldberg M, 421
Golden MR, 543
Gollub EL, 265
Gorbach PM, 543
Gotuzzo E, 103, 115
Gourde P, 177
Goyzueta G, 103
Gray RH, 590
Greenblatt RM, 143
Green DL, 49
Gregg CR, 160
Griffin RG, 291
Groseclose SL, 339
Gross M, 564, 572
Gurvey JE, 208

H

Haggitt RC, 564
Hagner D, 579

Handsfield HH, 228, S21

H

Han Y, 296
Harrison A, 152
Harwell TS, 265
Hawkins RV, 508
Hegeghougen HK, 184
Hellberg D, 197
Henderson S, 303
Herrera GA, 431
Hillier SL, 96
Hipp S, 296
Hobbs MM, 381
Hoff GL, 291
Hoffman I, 381
Hoffman V, 82
Höjer B, 491
Hollins L, 121
Holmes KK, 543
Hook EW III, 4, 87, 103, 127, 232, 272, 286, 329, 388, 450, 496, 531, 584
Hopkins F, 504
Horton S, 564
Howell MR, 519
Hser Y-L, 82
Htun Y, 556
Hubbard RA, 303
Hwang L-Y, 121

I

Irwin DE, 286
Irwin KL, 431
Ismail M, 137

J

Jackson TP, 96
Jafurs WJ Sr, 303
Jang D, 504
Jensen RL, 160
Johnson AP, 160
Johnson RB, 369, 531
Joly JR, 410
Jones RB, 369, 552
Jones SB, 404
Jordan NN, 103
Juhász J, 177

K

Kahn R, 108
Kalibbala S, 590
Kambugu F, 483
Kassler WJ, 232, 537
Katz BP, 26
Kaufman JA, 184
Kazembe P, 381
Kelaghan J, 127, 329, 450
Kelle JK, 579
Kell P, 531
Kelly CW, 564, 572
Kendall C, 108
Kidula N, 476
Kimball AM, 537
Kissinger P, 108, 281
Klausner JD, 335, 548
Kohl KS, 201
Koumans EH, 508
Koutsky LA, 392
Krepel J, 504
Krüger Kjaer S, 325
Kulasingam S, 166
Kyriakis, KP, 43

L

Lafferty WE, 537
Laisi R, 531
Lappin M, 137
Larsen SA, 426
La Ruche G, 191
Laumann EO, 250
Lavioe R, 317
LeClerc R, 317
Lee FK, 329, 426
Leone PA, 286
Leong MG, 556
Levine H, 564
Levine WC, 339
Leviton LC, 87
Lewis LM, 438, 472
Li C, 590
Li L, 87
Limpakarnjanarat K, 67
Livengood CH III, 137
Ljubicic M, 12
Long BJ, 137
Lörincz AT, 303
Low N, 404
Lurie M, 152
Lutalo T, 590
Lytle CD, 216

M

Macaluso M, 4, 127, 329, 450
 MacCornack R, 537
 Maguire A, 500
 Mahony J, 504
 Malotte K, 584
 Mangione-Smith R, 309
 Mann D, S26
 Mårdh P-A, 197
 Marquez C, 157
 Martens MG, 137
 Martin DH, 286, 369, 531
 Massanga M, 508
 Mässe B, 317
 Mastro TD, 67
 Mathur U, 143
 Matson P, 1
 Maxwell AE, 463
 McCormack WM, 531
 McGee ZA, 160
 McGlynn EA, 309
 McKee KT Jr, 519
 McNairn D, 590
 Meehan MP, 590
 Mehendale S, 55
 Meijer CJLM, 325
 Mertz GJ, 226
 Messon N, 191
 Meyerson B, 399
 Middlekauff SL, 431
 Middlestadt SE, 584
 Miller WC, 381
 Miotti P, 143
 Miret M, 500
 Modarress KJ, 303
 Mogilevskina I, 197
 Moran J, 508
 Morar NS, 374
 Morré SA, 325
 Morse S, S8, 63
 Moseley K, 108
 Mousavi N, 303
 Msellati P, 191
 Muic V, 12
 Munk C, 325
 Muñoz D, 115
 Muse A, 296
 Muth JB, 345
 Muth SQ, 49, 93, 345
 Myers L, 281

N

Nagelkerke NJD, 33
 Nahmias A, 329, 426
 Nelson AL, 137
 Niccolai LM, 281
 Nkata E, 381
 Noba V, 191
 Nopkesom T, 67
 Norris AE, 17
 Nsubuga PSJ, 483
 Nuwaha F, 483, 491

O

Ogonor JI, 184
 Okonofua FE, 184
 O'Leary J, 309
 Omar RF, 177
 Ombratte J, 476
 Omega Study Group, 317
 Omorodion FI, 184
 Orr DP, 26
 Otis J, 317

P

Paffel J, 121
 Paradise M, 564
 Paree MS, 431
 Parent R, 317
 Paris M, 103
 Parker EK, 213
 Parker KA, 508
 Pastore LM, 96
 Patel J, 504
 Pate MS, 232
 Piot P, 244
 Pluck ND, 531
 Poll PA, 325
 Potterat JJ, 49, 93, 345
 Poulin C, 410
 Pozniak AL, 404

Q

Quinn TC, 55, 519, 551, 590

R

Rabe LK, 96
 Rajamanoharan S, 404
 Rakai Project Team, 590
 Ramjee G, 374
 Ramstedt K, 390
 Rathbun KC, 350
 Reed AW, 381
 Reitano M, 364
 Remis RS, 317
 Rhodes P, 421
 Rice J, 108
 Richards EP III, 350
 Richéy CM, 4, 272, 496
 Rietmeijer CA, 95, 584
 Ringuet J, 410
 Rioux JE, 177
 Risbud A, 55
 Risser JMH, 121
 Risser WL, 121
 Roberts D, 213
 Roberts MC, 157
 Rocha E, 426
 Rodriguez-Trias H, S48
 Rompalo A, 55
 Ronald A, 517
 Rosenberg D, 108
 Rosenberg MD, 208
 Rosen T, 527
 Rosenthal SL, 438, 472
 Ross M, 444

R

Rothenberg RB, 345
 Royce RA, 96
 Rudy B, 265
 Ryncarz A, 1

S

Sagov S, 137
 Sande J, 476
 Sangkhamanya S, 67
 Savitz DA, 96
 Schachter J, 241, 279, S8

S

Schmid DS, 67
 Schwebke JR, 286, 496
 Scioneaux J, 201
 Selke S, 221
 Serwadda D, 590
 Sewankambo NK, 590
 Sheehan KL, 137
 Shepherd ME, 55
 Shivkar LK, 358
 Shriver M, S42
 Siegal HA, 87
 Silver S, 143
 Skinner E, 364
 Somse P, 508
 Soper DE, 137
 Spitters CE, 286
 Sproston A, 504
 St. Louis ME, 339, 421, 426
 Stamm WE, 392
 Stanberry LR, 438, 472
 Steen R, S12
 Steiner MJ, 459
 Stephens J, 272
 Stergachis A, S44
 Stern J, 364
 Stewart FH, S1
 Stoll BJ, 426
 Stone KM, 228
 Stoner B, 584
 Stratton JD, 286
 Succop PA, 438, 472
 Suchland RJ, 392
 Surawicz C, 564
 Sweet RL, 137
 Sylla-Koko F, 191

T

Tabet SR, 564, 572
 Tabidze IL, 426
 Tambe P, 426
 Taylor JE, 49
 Taylor-Robinson D, 160
 Temin MT, 184
 Temmerman M, 476
 Thomas JC, 286
 Thorp JM, 137
 Thorp JM Jr, 96
 Tremblay MJ, 177
 Trino R, 265
 Troutman GL, 303

V

Valappil T, 450
 Vall Mayans M, 500
 Van De Laar MJW, 33
 Van Den Brule AJC, 325
 Vandevanter N, 584
 Van Duynhoven YTHP, 33
 Vermund SH, 103
 Vinclette J, 317
 Vodopija I, 12
 Voigt RF, 431

W

Wabwire-Mangen F, 590
 Waites K, 496
 Wald A, 1, 364
 Warda US, 463
 Warner L, 459
 Wasserheit JN, 228, 549, S28

W

Watts DM, 115
 Wawer MJ, 590
 Weber AE, 374
 Wee S, 593
 Welfens-Ekra C, 191
 Weniger BG, 67
 White HA, 49
 White SD, 213
 Whittington WLH, 543
 WIHS Collaborative Study Group, 143
 Wilkinson D, 152
 Wilkinson TH, 291
 Williams M, 444
 Wong ML, 593
 Woodhouse DE, 345
 Wools KK, 26
 Wozniak A, 213
 Wright JM, 556

X

Xia M, 157

Y

Yarber WL, 399
 Yi A, 115
 Yorkman S, 265
 Youm Y, 250

Z

Zaidi AA, 339
 Zenilman JM, 75, 286
 Zimba D, 381
 Zimmerman-Rogers H, 49

INDEX OF SUBJECTS

A

Abortion, induced, STD occurrence and, 197
 Accelerated Campaign to Enhance STD Services (ACCESS) for youth, S28, S42
 Adolescents
 black/Hispanic, condom use by, 17, 463
 with chlamydia, gonorrhea, or trichomoniasis, subsequent STDs in, 26
 concurrent sex partners of, 208
 female
 chlamydial infection in, subsequent STDs and, 26
 chlamydia screening for, health and cost-benefits of, 309
 locus of control for general health and STD acquisition among, 472
 incarcerated/detained
 preventive education for, 265
 STD screening for, 265
 STD health care for
 assessment of, in Nigeria, 184
 CDC pilot projects for, S28, S42
 Africa, douching in pregnancy in, STD prevalence and, 191
 African Americans
 bacterial vaginosis
 genital cleansing practices and, 404
 in pregnancy, 96
 young, condom use by, 17, 463
 AIDS. *See* Human immunodeficiency virus infection
 Alcohol abuse. *See also* Substance abuse
 high-risk sexual behavior and, 87
 Antibiotic resistance, gonococcal, in India, 358
 Aral, Sevgi, O., ASTDA Achievement Award recipient, 243
 Army recruits, female, chlamydia control measures for, 519
 ASTDA Achievement Awards, 243, 551

B

Bacterial vaginosis
 genital cleansing practices and, 404
 incidence and prevalence estimates for, S2
 0.75% metronidazole gel for, 137
 in pregnancy, race/ethnicity and, 96
 Barrier contraceptives. *See* Condoms
 Bayes' theorem-based assessment of, VDRL screening miss rates, 12
 Behavior. *See* Sexual behavior
 Bites, human penile, genital ulcer due to, 527
 Blacks. *See* African Americans; Race/ethnicity

C

Calendar blister packaging, treatment compliance and, 556
 Cancer, cervical, in HIV-infected women, 500
 Centers for Disease Control and Prevention (CDC)
 pilot projects for adolescent care of, S28, S42
 prevention agenda for genital herpes of, 228
 Central African Republic, low-cost care delivery in, 508, 517 (editorial)
 Cervical cancer, in HIV-infected women, 500
 Chlamydial infection
 in adolescents, girls, subsequent STDs and, 26
 doxycycline for, measured vs. self-reported compliance with, 272, 279 (editorial)
 efficacy notification (interview) periods for, 49
 estimated incidence and prevalence of, in 1996, 339
 incidence and prevalence estimates for, S2
 ligase chain reaction testing for, pooled urine specimens for, 504
 newly available and future laboratory tests for, S8
 partner notification for, among private sector clinicians, 543
 PCR-detected, prevalence of and risk factors for, 325
 point-of-care tests for, 232
 predictors of, in Kenyan women, 476
 prevalence of, in injection vs. noninjection drug users, 410
 recurrent, risk assessment and management for, 4
 screening for
 follow-up rates after, 496
 time to treatment after, 421, 496

 in young women, health and cost-benefits of, 309
 in sex workers, in Peru, 103
 specimens for
 adequacy of, 579
 stability of during transport, 213
 trovafloxacin for, 369
 vs. doxycycline, 531
Chlamydia trachomatis, Hybrid Capture II and PACE 2 nucleic acid probe tests for, 303

Ciprofloxacin, gonococcal resistance to, in India, 358

Client education. *See* Education

Cocaine use. *See also* Substance abuse

 high-risk sexual behavior and, 82
 selling of sex and, 444

Coital diary, for sexual behavior reporting, vs. recall questionnaire, 374

College students, attitudes of toward vaccination for genital herpes, 438

Commercial sex workers. *See* Sex workers

Compliance

 calendar blister packaging and, 556
 measured vs. self-reported, for doxycycline for chlamydial infection, 272, 279 (editorial)

Computers

 HSV prevention education programs for, 364
 Internet use for health information with, 548 (letter)

Concurrent sex partnership, in adolescence, 208

Condoms

 failure of, in high-risk population, 450, 459 (editorial)
 integrity of, laboratory tests of, 216
 prophylactic efficacy of, prospective study of, 127
 use of

 by black/Hispanic youth, 17, 463

 by injection drug-using male prostitutes, 93 (letter)

 self-reported

 by STD clinic clients, 286

 validity of, 459 (editorial)

 by sex workers

 in Peru, 115

 in Singapore, 593

 by Ugandan STD patients, predictors of, 491

Core theory dynamics, geographic information system and, 75

Core transmission

 of gonorrhea, field intervention and, 296
 of syphilis, 108

Crack cocaine. *See also* Substance abuse

 high-risk sexual behavior and, 82

 selling of sex for, 444

D

Developing countries

 low-cost care delivery in, 508, 517 (editorial)

STD syndrome packets for, 152

Diary, coital, for sexual behavior reporting, vs. recall questionnaire, 374

DNA, HSV, in semen, 1

Douching

 bacterial vaginosis and, 404

 in pregnant African women, STD prevalence and, 191

Doxycycline

 for chlamydial infection, measured vs. self-reported compliance with, 272, 279 (editorial)

 vs. trovafloxacin, for chlamydial infection, 531

Drug abuse. *See* Substance abuse

Drug resistance, gonococcal, in India, 358

Drug therapy. *See also* Treatment

 compliance with

 calendar blister packaging and, 556

 measured vs. self-reported, in chlamydial infection, 272, 279 (editorial)

E

Education
 preventive
 for genital herpes, interactive computer-based program for, 364
 for incarcerated/detained male adolescents, 265
Websites for, 548 (letter)

ELISPOT, for syphilis, 426

Endocervical specimens, for chlamydial infection
 adequacy of, 579
 stability of during transport, 213

Enzyme-linked immunospot assay (ELISPOT), for syphilis, 426

Epidemiologic mass treatment and syndrome management, for STDs, S12, S21

Epidemiology
 geographic information system and, 75
 of gonorrhea, in Greek males, 43
 of HSV-2 vs. HIV-1, 67
 incidence and prevalence estimates in, S2
 for chlamydial infection, 339
 social network analysis in, 108, 250, 262 (editorial)
 of syphilis
 core transmitters of, 108
 during waning years of epidemic, 121

Ethnicity. *See* Race/ethnicity

G

Gay men, hepatitis B vaccination status of, 317

Genital cleansing practices
 bacterial vaginosis and, 404
 in pregnant African women, STD prevalence and, 191

Genital herpes. *See* Herpes simplex virus infection

Genital ulcers
 due to human penile bite, 527
 etiology of, in India, 55, 63 (editorial)
 newly available and future laboratory tests for, S8

Gen-Probe PACE 2 assay
 for *C. trachomatis*
 vs. Hybrid Capture test, 303
 specimen stability during transport and, 213
 for *N. gonorrhoeae*, vs. Hybrid Capture test, 303

Geographic information system, for epidemiologic studies, 75

Gonococcal salpingitis, mucosal TNF- α concentration in, sloughing of ciliated cells and, 157

Gonorrhea
 in adolescent girls, subsequent STDs and, 26
 core intervention for, 296
 drug resistance in, in India, 358
 in Greek males, epidemiology of, 43
 Hybrid Capture II and PACE 2 nucleic acid probe tests for, 303
 incidence and prevalence estimates for, S2
 newly available and future laboratory tests for, S8
 in Peruvian sex workers, 103
 predictors of, in Kenyan women, 476
 prevalence of, in injection vs. noninjection drug users, 410
 reemergence of in Sweden, 390

Greece, male gonorrhea in, epidemiology of, 43

H

Haemophilus ducreyi, newly available and future laboratory tests for, S8

Health care, forecast for, S49

Health Hold Orders, 345, 350 (editorial)

Hepatitis B
 incidence and prevalence estimates for, S2
 vaccination for, among male homosexuals, 317

Herpes simplex virus DNA, in semen, 1

Herpes simplex virus infection
 CDC prevention agenda for, 228
 incidence and prevalence estimates for, S2
 newly available and future laboratory tests for, S8
 preventive education for, interactive computer-based program for, 364
 recurrent vs. first-episode, differential diagnosis of, 221, 227 (editorial)

seroprevalence of in female STD clinic clients, epidemiologic and behavioral correlates of, 329

type 2, epidemiology of, vs. of HIV-1, 67

vaccination for, college students' attitudes toward, 438

High-risk sexual behavior

 in adolescents, concurrent sex partners and, 208
 alcohol abuse and, 87
 cocaine use and, 82
 condom failure and, 450, 459 (editorial)
 crack cocaine use and, 444
 self-reported, by STD clinic clients, 286

Hispanics, young, condom use by, 17, 463

History. *See* Sexual history

Homosexuals, male, hepatitis B vaccination status of, 317

Human immunodeficiency virus infection
 cervical cancer in, 500
 disclosure of to sexual partners, 281
 genital ulcer disease and, in India, 55, 63 (editorial)
 incidence and prevalence estimates for, S2
 male trichomonal urethritis and, 381, 388 (letter)
 prevalence of, in injection vs. noninjection drug users, 410
 prevention of, global priorities for, 244 (Parran Award Lecture)

Risk for

 alcohol abuse and, 87
 cocaine use and, 82
 in sex workers, in Peru, 115
STD incidence and, in infected vs. high-risk uninfected women, 143
surveillance programs for, 291
testing for, urine vs. serum specimens for, 590
 type 1, epidemiology of, vs. of HSV-2, 67

Human papillomavirus infection, incidence and prevalence estimates for, S2

Human T-cell leukemia virus infection, in sex workers, in Peru, 115

Hume, John Chandler, 119 (obituary)

Hybrid Capture II test, vs. Pace 2 test, 303

I

Immunization
 for genital herpes, college students' attitudes toward, 438
 for hepatitis B, among male homosexuals, 317

Incarcerated/detained persons

 adolescent male, preventive education for, 265
 female, in-jail acquisition of trichomoniasis in, 335
 Health Hold Orders and, 345, 350 (editorial)
 STD testing policies and practices for, 431

Incidence rates. *See* Epidemiology and specific infections**I**ndia

 genital ulcer disease in, etiology of, 55, 63 (editorial)
 N. gonorrhoeae auxotypes, serotypes, and drug sensitivity in, 358

Information technology, in STD control, S23, S26**I**njection drug users. *See also* Substance abuse

 chlamydial, gonococcal, and HIV infection prevalence in, 410
 incomplete partner notification by, forgetting as cause of, 166
 male, sex hustling by, 93

Internet, use of for health information, 548 (letter)**I**ntravenous drug use. *See* Injection drug use**I**nvoluntary detention, for STD testing, 345, 350 (editorial)**J**

Jails
 preventive education in, 265
 STD testing in, 431
 trichomoniasis acquisition in, 335

Jones, Robert B., Thomas Parran Award recipient, 551, 552**K**

Kenya, predictors of female chlamydial and gonococcal infection in, 476

L

Laboratory tests. *See also* specific tests
 for chlamydial infection
 endocervical specimen adequacy for, 579
 in Kenyan women, 476

pooled urine specimens for, 504
 specimen adequacy for, 579
 specimen stability during transport for, 579
 enzyme-linked immunospot assay (ELISPOT), for syphilis, 426
 for gonococcal infection, in Kenyan women, 476
 for HIV testing, urine vs. serum specimens for, 590
 newly available and future, for non-HIV STDs, 8
 PCR, for chlamydial infection, 325
 Leukocyte esterase urine dipstick testing, for chlamydial and gonococcal infection, in Kenyan women, 476
 Ligase chain reaction testing, for chlamydial infections, pooled urine specimens for, 504
 Locus of control, in female adolescents, STD acquisition and, 472
 Low-income women, barriers to seeking care among, 399

M

Malawian, trichomonal urethritis in, 381
 Male prostitution, substance abuse and, 93 (letter)
 Managed care, information technology in STD control in, S23, S26
 Metronidazole gel (0.75%), for bacterial vaginosis, 137
 Military recruits, female, chlamydia control measures for, 519
 Monogamy, condom use by low-income minority youth and, 17
 Mucosal toxicity, of nonoxynol-9, reduction of by thermoreversible gel, 177
 Mucosal tumor necrosis factor- α , in gonococcal salpingitis, sloughing of ciliated cells and, 157
 Multiplex polymerase chain reaction, for genital ulcer disease diagnosis, in India, 55, 63 (editorial)

N

Neisseria gonorrhoeae. *See also* Gonorrhea
 auxotypes, serotypes, and drug sensitivity of, in India, 358
 Hybrid Capture II and PACE 2 nucleic acid probe tests for, 303
 3.05 β -lactamase plasmid of, conjugal transfer of, 157
 newly available and future laboratory tests for, 88
 Network analysis
 of racial/ethnic differences in STD prevalence, 108, 262 (editorial)
 of syphilis transmission, 108
 Networking, information technology for, in managed care, S23, S26
 Nigerian adolescents, STD health care for, assessment of, 184
 Nonoxynol-9
 mucosal toxicity of, reduction of by thermoreversible gel, 177
 as rectal microbicide, safety and toxicity of, 564, 572

P

PACE 2 test
 for *C. trachomatis*
 vs. Hybrid Capture test, 303
 specimen stability during transport and, 213
 for *N. gonorrhoeae*, vs. Hybrid Capture test, 303
 Packaging, user-friendly, treatment compliance and, 556
 Parran Award Lectures, 244, 552
 Partner notification
 for chlamydial infections
 among private sector clinicians, 543
 notification (interview) periods for, 49
 factors influencing, in Uganda, 483
 for HIV infection, 281
 for syphilis control, 201
 Partner reporting, incomplete, forgetting as cause of, 166
 Penicillin, gonococcal resistance to, in India, 358
 Penis, human bite to, genital ulcer due to, 527
 Peru
 sex worker in, HIV, HTLV-I/II, and syphilis in, 115
 sex workers in, gonococcal and chlamydia infections in, 103
 Pharmacists, in STD prevention and control, S44, S48
 Piot, Peter, Thomas Parran Award recipient, 243, 244
 Police power, for involuntary detention for STD testing, 345, 350 (editorial)
 Polymerase chain reaction
 for chlamydial infection, prevalence and risk factor correlates for, 325
 for genital ulcer disease, in India, 55, 63 (editorial)

Pregnancy
 bacterial vaginosis in, race/ethnicity and, 96
 douching in, STD prevalence and, in Africa, 191
 Prevalence rates. *See* Epidemiology and specific infections
 Preventive education
 for genital herpes, interactive computer-based program for, 364
 for incarcerated/detained male adolescents, 265
 Websites for, 548 (letter)

Prisoners. *See* Incarcerated/detained persons
 Privatization, of STD clinics, quality review for, 537
 Prostitutes. *See* Sex workers

Q

Quality review, for privatized STD clinics, 537
 Questionnaire, recall, for sexual behavior reporting, vs. coital diary, 374
 Quinn, Thomas, ASTDA Achievement Award recipient, 551

R

Race/ethnicity
 bacterial vaginosis and
 genital cleansing practices and, 404
 in pregnancy, 96
 condom use and, 17, 463
 Rapid tests, for *C. trachomatis* infection, 232, 241 (editorial)
 Recall questionnaire, for sexual behavior reporting, vs. coital diary, 374
 Rectal microbicide, nonoxynol-9 as, safety and toxicity of, 564, 572
 Research, professional relationships in, 552 (Parran Award Lecture)
 Risk factors. *See also* Sexual behavior
 for chlamydial infection, in Kenyan women, 476
 for chlamydial reinfection, 4
 for gonococcal infection, in Kenyan women, 476
 for HIV infection
 alcohol abuse as, 87
 cocaine use as, 82
 in injection vs. noninjection drug users, 410
 for PCR-detected chlamydial infection, 325
 for STDs
 douching in pregnancy as, in Africa, 191
 history of induced abortion as, 197
 Risk management strategies, for incarcerated/detained male adolescents, 265

S

Salpingitis, gonococcal, mucosal TNF- α concentration in, sloughing of ciliated cells and, 157
 Screening
 for chlamydial infection
 endocervical specimen adequacy for, 579
 follow-up rates after, 496
 in Kenyan women, 476
 rapid tests for, 232, 241 (editorial)
 time to treatment after, 421, 496
 in young women, health and cost-benefits of, 309
 for gonococcal infection, in Kenyan women, 476
 involuntary detention for, 345, 350 (editorial)
 in jail populations, 431
 for syphilis, miss rates for, Bayes' theorem-based assessment of, 12
 Self-reporting
 of compliance with doxycycline for chlamydial infection, 272, 279 (editorial)
 of condom use
 reliability of, 286
 validity of, 459 (editorial)
 of sexual behavior, recall questionnaire vs. coital diary for, 374
 of sexual history, reliability of, 33, 286
 Semen, HSV DNA in, 1
 Serum specimens. *See also* Specimens
 for HIV testing, vs. urine specimens, 590
 Sex partnership, concurrent, in adolescence, 208
 Sexual behavior
 of adolescents, concurrent sex partners and, 208

high-risk
 in adolescents, concurrent sex partners and, 208
 alcohol abuse and, 87
 cocaine use and, 82, 444
 condom failure and, 450, 459 (editorial)
 reporting of
 recall questionnaire vs. coital diary for, 374
 reliability of, 33, 286
 of young low-income African Americans/Hispanics, condom use and, 17

Sexual history
 coital diary vs. recall questionnaire for, 374
 elicitation of, practice patterns for, 584
 self-reported, reliability of, 33

Sexually transmitted disease clinic clients
 female, HSV seroprevalence in, epidemiologic and behavioral correlates of, 329
 high-risk sexual behavior of. *See also* Sexual behavior, high-risk
 cocaine use and, 82
 self-reported condom use by, 286
 self-reported high-risk behavior by, 286

Sexually transmitted disease clinics
 low-cost care delivery in, in Central African Republic, 508, 517 (editorial)
 privatized, quality review of, 537
 quality of care in, for Nigerian adolescents, 184

Sexually transmitted diseases. *See also specific diseases*
 acquisition of, female adolescent locus of control and, 472
 among HIV-infected vs. high-risk uninfected women, 143
 barriers to seeking care for, 399
 control of
 future directions in, 549
 information technology in, S23, S26
 pharmacists' role in, S44, S48
 epidemiologic mass treatment and syndrome management for, S12, S21
 incidence and prevalence estimates for, S2
 non-HIV, newly available and future laboratory tests for, S8
 prevalence of, racial/ethnic group differences in, 250
 research in, professional relationships in, 552 (Parran Award Lecture)
 risk of. *See* Risk factors
 subsequent, in adolescents with chlamydia, gonorrhea, or trichomoniasis, 26
 testing for. *See* Laboratory tests; Screening
 treatment of. *See* Treatment

Sexually Transmitted Diseases, most frequently cited article from, 549

Sexually transmitted disease syndrome packets, 152
 calendar blister packaging for, 556

Sexual network analysis. *See* Social network analysis

Sexual partnerships. *See also under* Partner
 geography of, core theory dynamics and, 75

Sex workers
 condom use by
 in Peru, 115
 in Singapore, 593
 gonococcal and chlamydial infections in, in Peru, 103
 HIV, HTLV-I/II, and syphilis in, in Peru, 115
 involuntary detention of, for STD testing, 345, 350 (editorial)
 male, substance abuse by, 93 (letter)
 sex selling for drugs by, 444
 sexual behavior reporting by, recall questionnaire vs. coital diary for, 374

Singapore, condom use by sex workers in, 593

Social network analysis
 of racial/ethnic differences in STD prevalence, 108, 262 (editorial)
 of syphilis transmission, 108

Spain, cervical cancer in HIV-infected women in, 500

Specimens
 endocervical chlamydial
 adequacy of, 579
 stability of during transport, 213
 pooled urine, for ligase chain reaction testing for *C. trachomatis*, 504
 urine vs. serum, for HIV testing, 590

Spermicides
 mucosal toxicity of, reduction of by thermoreversible gel, 177
 as rectal microbicides, safety and toxicity of, 564, 572

STD Forum: Conspiracy to Innovate
 goals of, S1
 papers presented at, S2-S50

Students, attitudes of toward vaccination for genital herpes, 438

Substance abuse
 chlamydial, gonococcal, and HIV infection prevalence and, 410
 high-risk sexual behavior and, 82
 in DIU offenders, 87
 in STD clinic clients, 82
 in substance abusers, 444

incomplete partner reporting for, forgetting as cause of, 166
 male prostitution and, 93 (letter)
 selling of sex and, 444

Surveillance, for HIV infection, 291

Sweden, gonorrhea reemergence in, 390

Syphilis
 core transmission of, 108
 enzyme-linked immunospot assay (ELISPOT) for, 426
 epidemiology of, during waning years of epidemic, 121
 incidence and prevalence estimates for, S2
 newly available and future laboratory tests for, S8
 partner notification for, 201
 in sex workers, in Peru, 115
 VDRL test for, miss rates for, Bayes' theorem-based assessment of, 12

T

Tetracycline, gonococcal resistance to, in India, 358

Third-world countries
 low-cost care delivery in, 508, 517 (editorial)
 STD syndrome packets for, 152

Thomas Parran Award Lectures, 244, 552

Transport, of *C. trachomatis* specimens, 213

Treatment
 barriers to seeking, 399
 low-cost delivery of, in Central African Republic, 508, 517 (editorial)
 in Nigerian adolescents, quality assessment for, 184
 presumptive, S21
 STD syndrome packets for, 152

Treatment compliance
 calendar blister packaging and, 556
 measured vs. self-reported, for doxycycline for chlamydial infection, 272, 279 (editorial)

Treponema pallidum. *See also* Syphilis
 newly available and future laboratory tests for, S8

Trichomonas vaginalis infection
 in adolescent girls, subsequent STDs and, 26
 incidence, diagnosis, and treatment of, 388 (letter)
 incidence and prevalence estimates for, S2
 in-jail acquisition of, 335

Trichomonas vaginalis urethritis, in Malawian men, 381

Trovafloxacin
 for chlamydial infections, 369
 vs. doxycycline, for chlamydial infection, 531

Tumor necrosis factor- α , in gonococcal salpingitis, sloughing of ciliated cells and, 157

U

Uganda
 condom use by STD patients in, predictors of, 491
 partner referral in, factors influencing, 483

Ulcers. *See* Genital ulcers

University students, attitudes of toward vaccination for genital herpes, 438

Urethritis, trichomonal, in Malawian men, 381

Urine specimens
 for HIV testing, vs. serum specimens, 590
 pooled, for ligase chain reaction testing, for chlamydial infections, 504

User-friendly packaging, treatment compliance and, 556

V

Vaccination

for genital herpes, college students' attitudes toward, 438
for hepatitis B, among male homosexuals, 317

Vaginal cleansing practices

bacterial vaginosis and, 404
in pregnant African women, STD prevalence and, 191

Vaginosis. *See* Bacterial vaginosis

VDRL test, miss rates for, Bayes' theorem-based assessment of, 12

Viruses, condom penetration by, laboratory tests and, 216

W

Water leak test, for condoms, efficacy of, 216

Websites, use of for health information, 548 (letter)

Wounds, human bite, of penis, genital ulcer and, 527

Y

Young adults

attitudes of toward vaccination for genital herpes, 438

low-income African American/Hispanic, condom use by, 17